[Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].

PubMed 2026 Open access

Read full text
Authors: X L Zhu, J Z Wang, H X Fu, Z L Xu, Y Y Chen, X D Mo, X H Zhang, L P Xu, X J Huang, Y Wang
DOI: 10.3760/cma.j.cn121090-20250630-00306
Cited by: 1

Abstract

Basiliximab may be used to treat GI-cGVHD, with hematologic and infection-related adverse event rates comparable to those of other systemic immunosuppressants. These findings suggest a potential therapeutic option for GI-cGVHD; however, larger prospective studies are needed to further evaluate its safety.

Publication details

Journal / source
PubMed
Volume
47
Issue
2
Pages
146–152
Publication date
14 February 2026
Language
ZH